Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors palbociclib, ribociclib, and abemaciclib are standard-of-care therapy for hormone receptor-positive advanced or metastatic breast cancer, based on randomized trials showing improved progression-free survival for all 3 drugs and overall survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnston, Stephen, Emde, Anna, Barrios, Carlos, Srock, Stefanie, Neven, Patrick, Martin, Miguel, Cameron, David, Janni, Wolfgang, Gnant, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415176/
https://www.ncbi.nlm.nih.gov/pubmed/37369022
http://dx.doi.org/10.1093/jncics/pkad045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415176/
https://www.ncbi.nlm.nih.gov/pubmed/37369022
http://dx.doi.org/10.1093/jncics/pkad045

Ejemplares similares